Citation

BibTex format

@article{Cortellini:2023:10.1016/S1470-2045(23)00056-6,
author = {Cortellini, A and Tabernero, J and Mukherjee, U and Salazar, R and Sureda, A and Maluquer, C and Ferrante, D and Bower, M and Sharkey, R and Mirallas, O and Plaja, A and Cucurull, M and Mesia, R and Dalla, Pria A and Newsom-Davis, T and Van, Hemelrijck M and Sita-Lumsden, A and Apthorp, E and Vincenzi, B and Di, Fazio GR and Tonini, G and Pantano, F and Bertuzzi, A and Rossi, S and Brunet, J and Lambertini, M and Pedrazzoli, P and Biello, F and D'Avanzo, F and Lee, AJX and Shawe-Taylor, M and Rogers, L and Murphy, C and Cooper, L and Andaleeb, R and Khalique, S and Bawany, S and Ahmed, S and Carmona-García, MC and Fort-Culillas, R and Liñan, R and Zoratto, F and Rizzo, G and Perachino, M and Doonga, K and Gaidano, G and Bruna, R and Patriarca, A and Martinez-Vila, C and Pérez, Criado I and Giusti, R and Mazzoni, F and Antonuzzo, L and Santoro, A and Parisi, A and Queirolo, P and Aujayeb, A and Rimassa, L and Diamantis, N and Bertulli, R and Fulgenzi, CAM and D'Alessio, A and Ruiz-Camps},
doi = {10.1016/S1470-2045(23)00056-6},
journal = {The Lancet Oncology},
pages = {335--346},
title = {SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry},
url = {http://dx.doi.org/10.1016/S1470-2045(23)00056-6},
volume = {24},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care. We aimed to investigate whether previous immunisation affects long-term sequelae in the context of evolving variants of concern of SARS-CoV-2. METHODS: OnCovid is an active registry that includes patients aged 18 years or older from 37 institutions across Belgium, France, Germany, Italy, Spain, and the UK with a laboratory-confirmed diagnosis of COVID-19 and a history of solid or haematological malignancy, either active or in remission, followed up from COVID-19 diagnosis until death. We evaluated the prevalence of COVID-19 sequelae in patients who survived COVID-19 and underwent a formal clinical reassessment, categorising infection according to the date of diagnosis as the omicron (B.1.1.529) phase from Dec 15, 2021, to Jan 31, 2022; the alpha (B.1.1.7)-delta (B.1.617.2) phase from Dec 1, 2020, to Dec 14, 2021; and the pre-vaccination phase from Feb 27 to Nov 30, 2020. The prevalence of overall COVID-19 sequelae was compared according to SARS-CoV-2 immunisation status and in relation to post-COVID-19 survival and resumption of systemic anticancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974. FINDINGS: At the follow-up update on June 20, 2022, 1909 eligible patients, evaluated after a median of 39 days (IQR 24-68) from COVID-19 diagnosis, were included (964 [50·7%] of 1902 patients with sex data were female and 938 [49·3%] were male). Overall, 317 (16·6%; 95% CI 14·8-18·5) of 1909 patients had at least one sequela from COVID-19 at the first oncological reassessment. The prevalence of COVID-19 sequelae was highest in the pre-vaccination phase (191 [19·1%; 95% CI 16·4-22·0] of 1000 patients). The prevalence was similar in the alpha-delta phase (110 [16·8%; 13·8-20&middo
AU  - Cortellini,A
AU  - Tabernero,J
AU  - Mukherjee,U
AU  - Salazar,R
AU  - Sureda,A
AU  - Maluquer,C
AU  - Ferrante,D
AU  - Bower,M
AU  - Sharkey,R
AU  - Mirallas,O
AU  - Plaja,A
AU  - Cucurull,M
AU  - Mesia,R
AU  - Dalla,Pria A
AU  - Newsom-Davis,T
AU  - Van,Hemelrijck M
AU  - Sita-Lumsden,A
AU  - Apthorp,E
AU  - Vincenzi,B
AU  - Di,Fazio GR
AU  - Tonini,G
AU  - Pantano,F
AU  - Bertuzzi,A
AU  - Rossi,S
AU  - Brunet,J
AU  - Lambertini,M
AU  - Pedrazzoli,P
AU  - Biello,F
AU  - D'Avanzo,F
AU  - Lee,AJX
AU  - Shawe-Taylor,M
AU  - Rogers,L
AU  - Murphy,C
AU  - Cooper,L
AU  - Andaleeb,R
AU  - Khalique,S
AU  - Bawany,S
AU  - Ahmed,S
AU  - Carmona-García,MC
AU  - Fort-Culillas,R
AU  - Liñan,R
AU  - Zoratto,F
AU  - Rizzo,G
AU  - Perachino,M
AU  - Doonga,K
AU  - Gaidano,G
AU  - Bruna,R
AU  - Patriarca,A
AU  - Martinez-Vila,C
AU  - Pérez,Criado I
AU  - Giusti,R
AU  - Mazzoni,F
AU  - Antonuzzo,L
AU  - Santoro,A
AU  - Parisi,A
AU  - Queirolo,P
AU  - Aujayeb,A
AU  - Rimassa,L
AU  - Diamantis,N
AU  - Bertulli,R
AU  - Fulgenzi,CAM
AU  - D'Alessio,A
AU  - Ruiz-Camps,I
AU  - Saoudi-Gonzalez,N
AU  - Garcia,Illescas D
AU  - Medina,I
AU  - Fox,L
AU  - Gennari,A
AU  - Aguilar-Company,J
AU  - Pinato,DJ
AU  - OnCovid,study group
DO  - 10.1016/S1470-2045(23)00056-6
EP  - 346
PY  - 2023///
SN  - 1213-9432
SP  - 335
TI  - SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry
T2  - The Lancet Oncology
UR  - http://dx.doi.org/10.1016/S1470-2045(23)00056-6
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36898391
UR  - https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00056-6/fulltext
VL  - 24
ER  -
Download